Clinical Review

Heparin-Induced Thrombocytopenia: Diagnosis

Author and Disclosure Information

The diagnosis of HIT is determined by combining clinical and serologic assessments. The 4Ts scoring strategy to determine the patient's probability of HIT is included here.


 

This is the third article in the series, "Heparin-Induced Thrombocytopenia." The remaining articles are Introduction; Presentation and History; Treatment/Management; and References.

Diagnosis

The diagnosis of HIT is determined by combining clinical and serologic assessment. HIT should be suspected in any patient who is in day 5 to 14 of heparin therapy and experiences a drop in platelet count of at least 50%, or in whom a new thrombotic event occurs (even if the patient is no longer receiving heparin therapy). The interpretation of all diagnostic information must be made in the context of the patient's clinical probability of HIT.15

A scoring system referred to as the 4Ts (thrombocytopenia, timing of platelet fall, thrombosis or other sequelae, and test interpretation) is used to help determine the patient's probability of HIT5,21,22 (similar to the scoring strategy shown in Table 22,11,23,24). The patient diagnosed with HIT must be positive for HIT antibodies and meet at least one additional criterion:

• A platelet count decrease of 30% to 50% below baseline, regardless of the actual value

• A venous or arterial thrombosis

• A skin lesion at the heparin injection site; and/or

• An anaphylactic reaction after IV bolus administration of heparin.15

This is the third article in the series, "Heparin-Induced Thrombocytopenia." The remaining articles are Introduction; Presentation and History; Treatment/Management; and References.

Recommended Reading

Is same-day discharge after PCI safe?
Federal Practitioner
Organizing Pneumonia and Pneumothorax Associated With Daptomycin Use
Federal Practitioner
Effect of Statins on Total Testosterone Levels in Male Veterans
Federal Practitioner
Venous Thromboembolism and Weight Changes in Veteran Patients Using Megestrol Acetate as an Appetite Stimulant
Federal Practitioner
Evaluation of the Conversion of the Brand Equivalent of Warfarin to Its Generic
Federal Practitioner
A Generation of Progress in Endocrinology, Especially Cardiovascular Endocrinology
Federal Practitioner
Cardiac Surgery—State-of-the-Heart Review
Federal Practitioner
Delta NT-proBNP: Better Marker of Neuroendocrine Pathways Blockade in Decompensated Congestive Heart Failure?
Federal Practitioner
Cardiovascular Disease Is a Risk Factor for Hip Fracture; Does Frailty Protect Against Cancer?; Choosing the Best Catheter for the Patient
Federal Practitioner
Understanding Heart Failure
Federal Practitioner